文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19 CAR-T细胞治疗复发/难治性实体器官移植相关PTLD的安全性与生存的真实世界证据

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
PubMed 文献 · Br J Haematol · 2023-05-02

这项多中心回顾性分析纳入22例复发/难治性实体器官移植相关PTLD成人患者,病理均为单形性B细胞型。CD19 CAR-T治疗后总缓解率64%(完全缓解55%),2年无进展生存率和总生存率分别为35%和58%,安全性及疗效与关键CAR-T数据相似。

要点

  • 22例复发/难治性SOT相关PTLD患者接受CD19 CAR-T治疗,总缓解率64%,完全缓解55%。
  • 细胞因子释放综合征发生率82%,3级和4级各1例(各5%);ICANS发生率73%,3级6例(27%)、4级2例(9%)。
  • 2年无进展生存率35%,2年总生存率58%;CAR-T后达到完全缓解与生存强相关。

核心结论

  • CD19 CAR-T治疗复发/难治性SOT相关PTLD的安全性和疗效与关键CAR-T数据相似,约三分之一患者获得持续缓解。

研究设计与样本

  • 多中心回顾性分析,纳入22例复发/难治性实体器官移植相关PTLD成人患者,病理均为单形性B细胞型。

主要发现

  • 既往移植类型:肾移植14例(64%)、肝移植3例(14%)、心脏移植2例(9%)、肠移植1例(5%)、肺移植1例(5%)、肾移植后胰腺移植1例(5%)。
  • 从实体器官移植到PTLD诊断的中位时间为107个月。
  • CAR-T前桥接治疗使用率55%,CAR-T输注前完全停用免疫抑制者占64%。
  • 细胞因子释放综合征18例(82%),其中3级1例(5%)、4级1例(5%);ICANS 16例(73%),其中3级6例(27%)、4级2例(9%)。
  • 总缓解率64%(完全缓解55%);CAR-T后移植物排斥3例(14%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD) is not well studied. We conducted a multicentre, retrospective analysis of adults with relapsed/refractory SOT-associated PTLD. Among 22 relapsed/refractory SOT-PTLD patients, the pathology was monomorphic B cell. Prior SOTs included 14 kidney (64%), three liver (14%), two heart (9%), one intestinal (5%), one lung (5%), and one pancreas after kidney transplant (5%). The median time from SOT to PTLD diagnosis was 107 months. Pre-CAR-T bridging therapy was used in 55% of patients, and immunosuppression was stopped completely before CAR-T infusion in 64%. Eighteen (82%) patients experienced cytokine release syndrome: one (5%) each grade (G) 3 and G4. The immune effector cell-associated neurotoxicity syndrome was observed in 16 (73%) patients: six (27%) G3 and two (9%) G4. The overall response rate was 64% (55% complete response). Three patients (14%) experienced allograft rejection after CAR-T. The two-year progression-free survival and overall survival rates were 35% and 58%, respectively. Additionally, the achievement of CR post-CAR-T was strongly associated with survival. Collectively, the safety and efficacy of CD19 CAR-T therapy in relapsed/refractory SOT-related PTLD appeared similar to pivotal CAR-T data, including approximately one-third of patients achieving sustained remission.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. McKenna M, Epperla N, Ghobadi A, et al. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br J Haematol. 2023. PMID: 37129856. doi:10.1111/bjh.18828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。